Current immunotherapies have helped many patients with advanced tumors, but some experts think that the odds of success would likely improve if we could treat tumors before they’ve progressed to late stages. However, more must first be known about cancer and immune cell interactions throughout tumor development, so Dr. Cong is creating a mouse model of lung cancer to analyze individual cells over time. Then, he plans to use computational modeling to compare and validate these findings with human tumor samples. This may allow Dr. Cong to identify key “druggable” events that could be targeted during tumor development and enhance immunotherapy’s effectiveness in patients.
Broad Institute of MIT and Harvard | All Cancers, Lung Cancer | 2016 | Aviv Regev, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
This September for Childhood Cancer Awareness Month, we look at new research, new treatments, and how we are working toward a future immune to childhood cancer.
This September for Gynecologic Cancer Awareness Month, we reflect on new treatments, research discoveries, and how CRI is making its impact on a future immune to cervical, ovarian, and uterine cancers.